Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andreas Helke who wrote (4206)	5/4/1998 5:45:00 PM
From: sam	of 6136

How Endostatin will work in humans is obviously still a big question mark and wont be resolved for a long time. If it does as well as with mice, of course, the ENMD shareholders will be nicely rewarded. But from AGPH's perspective, at least AGPH is playing in the right ballpark (as far as cancer treatment goes). Hopefully, AG3340 will be useful as well (we'll find out soon enough, I suspect). Now maybe somebody will take notice that AGPH has more than just Viracept going for it. And maybe some of the pressure on the stock will ease.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next